Food Chem Toxicol:血浆硒和尿中总砷的水平相互作用并影响前列腺癌风险

2017-06-26 AlexYang MedSci原创

最近,有研究人员调查了是佛血浆硒的水平可以影响砷暴露相关的前列腺癌(PC)风险。研究人员采用了一个案例-对照的研究方法,并包括了318名前列腺癌病人和318名年龄匹配的健康对照主体。研究利用HPLC-HG-AAS对尿砷情况进行了分析,并利用ICP-MS技术对血浆硒的水平进行了检测。研究发现,血浆硒的水平表现出了显著的剂量依赖并与前列腺癌表现出负相关关系。参与者血浆硒水平>28.06 μg/d

最近,有研究人员调查了是佛血浆硒的水平可以影响砷暴露相关的前列腺癌(PC)风险。研究人员采用了一个案例-对照的研究方法,并包括了318名前列腺癌病人和318名年龄匹配的健康对照主体。研究利用HPLC-HG-AAS对尿砷情况进行了分析,并利用ICP-MS技术对血浆硒的水平进行了检测。

研究发现,血浆硒的水平表现出了显著的剂量依赖并与前列腺癌表现出负相关关系。参与者血浆硒水平>28.06 μg/dL与≤19.13μg/dL相比,前列腺癌让步比(OR)和95%的置信区间(CI)为0.07(0.04-0.13)。多变量分析表明,具有尿总砷浓度>29.28μg/dL的参与者与≤29.28μg/dL相比,具有显著更高的前列腺癌OR(1.75,1.06-2.89)。而在低血浆硒水平和高尿总砷浓度组合表现中,前列腺癌OR呈指数级增加,并且在PSA≥20ng/ml存在互作。这也是第一次流行病学研究来检测血浆硒和尿总砷水平的组合效应对前列腺癌OR的作用。最后,研究人员指出,低水平的血浆硒外加高水平的尿总砷浓度可以导致侵入性前列腺癌显著的患病风险。

原始出处:

Hsueh YM, Su CT, Shiue HS et al. Levels of plasma selenium and urinary total arsenic interact to affect the risk for prostate cancer. Food Chem Toxicol. 17 June 2017.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2022557, encodeId=4ab0202255edf, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Mon Jan 01 21:44:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909209, encodeId=74fb19092095d, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Wed Jul 19 13:44:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715569, encodeId=34d61e1556939, content=<a href='/topic/show?id=a217e58972' target=_blank style='color:#2F92EE;'>#food#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7589, encryptionId=a217e58972, topicName=food)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68d031960225, createdName=ms6747015003810650, createdTime=Mon Jan 15 02:44:00 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061636, encodeId=bbb22061636a7, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Nov 17 18:44:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=220629, encodeId=18ac22062979, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCcmyvDOwDu2ZpuYyovmsD12IBHmUCwr5bZqNic2p50ogCxUAIj4YqJ3PsGwoXOhJPQAvicmu6RqOww/0, createdBy=a0bf1958339, createdName=七九九八, createdTime=Mon Jul 10 08:02:21 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218933, encodeId=fba221893365, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCcmyvDOwDu2ZpuYyovmsD12IBHmUCwr5bZqNic2p50ogCxUAIj4YqJ3PsGwoXOhJPQAvicmu6RqOww/0, createdBy=a0bf1958339, createdName=七九九八, createdTime=Wed Jul 05 22:22:49 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218116, encodeId=cba0218116db, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCcmyvDOwDu2ZpuYyovmsD12IBHmUCwr5bZqNic2p50ogCxUAIj4YqJ3PsGwoXOhJPQAvicmu6RqOww/0, createdBy=a0bf1958339, createdName=七九九八, createdTime=Mon Jul 03 12:09:08 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471542, encodeId=ec5d14e1542a1, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Wed Jun 28 13:44:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595971, encodeId=aeee15959e1b1, content=<a href='/topic/show?id=07bfe3495f1' target=_blank style='color:#2F92EE;'>#砷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73495, encryptionId=07bfe3495f1, topicName=砷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=863418313756, createdName=lishizhe, createdTime=Wed Jun 28 13:44:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216146, encodeId=261c2161460f, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Wed Jun 28 06:13:34 CST 2017, time=2017-06-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2022557, encodeId=4ab0202255edf, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Mon Jan 01 21:44:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909209, encodeId=74fb19092095d, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Wed Jul 19 13:44:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715569, encodeId=34d61e1556939, content=<a href='/topic/show?id=a217e58972' target=_blank style='color:#2F92EE;'>#food#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7589, encryptionId=a217e58972, topicName=food)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68d031960225, createdName=ms6747015003810650, createdTime=Mon Jan 15 02:44:00 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061636, encodeId=bbb22061636a7, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Nov 17 18:44:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=220629, encodeId=18ac22062979, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCcmyvDOwDu2ZpuYyovmsD12IBHmUCwr5bZqNic2p50ogCxUAIj4YqJ3PsGwoXOhJPQAvicmu6RqOww/0, createdBy=a0bf1958339, createdName=七九九八, createdTime=Mon Jul 10 08:02:21 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218933, encodeId=fba221893365, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCcmyvDOwDu2ZpuYyovmsD12IBHmUCwr5bZqNic2p50ogCxUAIj4YqJ3PsGwoXOhJPQAvicmu6RqOww/0, createdBy=a0bf1958339, createdName=七九九八, createdTime=Wed Jul 05 22:22:49 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218116, encodeId=cba0218116db, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCcmyvDOwDu2ZpuYyovmsD12IBHmUCwr5bZqNic2p50ogCxUAIj4YqJ3PsGwoXOhJPQAvicmu6RqOww/0, createdBy=a0bf1958339, createdName=七九九八, createdTime=Mon Jul 03 12:09:08 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471542, encodeId=ec5d14e1542a1, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Wed Jun 28 13:44:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595971, encodeId=aeee15959e1b1, content=<a href='/topic/show?id=07bfe3495f1' target=_blank style='color:#2F92EE;'>#砷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73495, encryptionId=07bfe3495f1, topicName=砷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=863418313756, createdName=lishizhe, createdTime=Wed Jun 28 13:44:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216146, encodeId=261c2161460f, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Wed Jun 28 06:13:34 CST 2017, time=2017-06-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2022557, encodeId=4ab0202255edf, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Mon Jan 01 21:44:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909209, encodeId=74fb19092095d, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Wed Jul 19 13:44:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715569, encodeId=34d61e1556939, content=<a href='/topic/show?id=a217e58972' target=_blank style='color:#2F92EE;'>#food#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7589, encryptionId=a217e58972, topicName=food)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68d031960225, createdName=ms6747015003810650, createdTime=Mon Jan 15 02:44:00 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061636, encodeId=bbb22061636a7, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Nov 17 18:44:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=220629, encodeId=18ac22062979, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCcmyvDOwDu2ZpuYyovmsD12IBHmUCwr5bZqNic2p50ogCxUAIj4YqJ3PsGwoXOhJPQAvicmu6RqOww/0, createdBy=a0bf1958339, createdName=七九九八, createdTime=Mon Jul 10 08:02:21 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218933, encodeId=fba221893365, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCcmyvDOwDu2ZpuYyovmsD12IBHmUCwr5bZqNic2p50ogCxUAIj4YqJ3PsGwoXOhJPQAvicmu6RqOww/0, createdBy=a0bf1958339, createdName=七九九八, createdTime=Wed Jul 05 22:22:49 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218116, encodeId=cba0218116db, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCcmyvDOwDu2ZpuYyovmsD12IBHmUCwr5bZqNic2p50ogCxUAIj4YqJ3PsGwoXOhJPQAvicmu6RqOww/0, createdBy=a0bf1958339, createdName=七九九八, createdTime=Mon Jul 03 12:09:08 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471542, encodeId=ec5d14e1542a1, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Wed Jun 28 13:44:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595971, encodeId=aeee15959e1b1, content=<a href='/topic/show?id=07bfe3495f1' target=_blank style='color:#2F92EE;'>#砷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73495, encryptionId=07bfe3495f1, topicName=砷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=863418313756, createdName=lishizhe, createdTime=Wed Jun 28 13:44:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216146, encodeId=261c2161460f, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Wed Jun 28 06:13:34 CST 2017, time=2017-06-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2022557, encodeId=4ab0202255edf, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Mon Jan 01 21:44:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909209, encodeId=74fb19092095d, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Wed Jul 19 13:44:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715569, encodeId=34d61e1556939, content=<a href='/topic/show?id=a217e58972' target=_blank style='color:#2F92EE;'>#food#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7589, encryptionId=a217e58972, topicName=food)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68d031960225, createdName=ms6747015003810650, createdTime=Mon Jan 15 02:44:00 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061636, encodeId=bbb22061636a7, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Nov 17 18:44:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=220629, encodeId=18ac22062979, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCcmyvDOwDu2ZpuYyovmsD12IBHmUCwr5bZqNic2p50ogCxUAIj4YqJ3PsGwoXOhJPQAvicmu6RqOww/0, createdBy=a0bf1958339, createdName=七九九八, createdTime=Mon Jul 10 08:02:21 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218933, encodeId=fba221893365, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCcmyvDOwDu2ZpuYyovmsD12IBHmUCwr5bZqNic2p50ogCxUAIj4YqJ3PsGwoXOhJPQAvicmu6RqOww/0, createdBy=a0bf1958339, createdName=七九九八, createdTime=Wed Jul 05 22:22:49 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218116, encodeId=cba0218116db, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCcmyvDOwDu2ZpuYyovmsD12IBHmUCwr5bZqNic2p50ogCxUAIj4YqJ3PsGwoXOhJPQAvicmu6RqOww/0, createdBy=a0bf1958339, createdName=七九九八, createdTime=Mon Jul 03 12:09:08 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471542, encodeId=ec5d14e1542a1, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Wed Jun 28 13:44:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595971, encodeId=aeee15959e1b1, content=<a href='/topic/show?id=07bfe3495f1' target=_blank style='color:#2F92EE;'>#砷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73495, encryptionId=07bfe3495f1, topicName=砷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=863418313756, createdName=lishizhe, createdTime=Wed Jun 28 13:44:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216146, encodeId=261c2161460f, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Wed Jun 28 06:13:34 CST 2017, time=2017-06-28, status=1, ipAttribution=)]
    2017-11-17 sjq027
  5. [GetPortalCommentsPageByObjectIdResponse(id=2022557, encodeId=4ab0202255edf, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Mon Jan 01 21:44:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909209, encodeId=74fb19092095d, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Wed Jul 19 13:44:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715569, encodeId=34d61e1556939, content=<a href='/topic/show?id=a217e58972' target=_blank style='color:#2F92EE;'>#food#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7589, encryptionId=a217e58972, topicName=food)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68d031960225, createdName=ms6747015003810650, createdTime=Mon Jan 15 02:44:00 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061636, encodeId=bbb22061636a7, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Nov 17 18:44:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=220629, encodeId=18ac22062979, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCcmyvDOwDu2ZpuYyovmsD12IBHmUCwr5bZqNic2p50ogCxUAIj4YqJ3PsGwoXOhJPQAvicmu6RqOww/0, createdBy=a0bf1958339, createdName=七九九八, createdTime=Mon Jul 10 08:02:21 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218933, encodeId=fba221893365, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCcmyvDOwDu2ZpuYyovmsD12IBHmUCwr5bZqNic2p50ogCxUAIj4YqJ3PsGwoXOhJPQAvicmu6RqOww/0, createdBy=a0bf1958339, createdName=七九九八, createdTime=Wed Jul 05 22:22:49 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218116, encodeId=cba0218116db, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCcmyvDOwDu2ZpuYyovmsD12IBHmUCwr5bZqNic2p50ogCxUAIj4YqJ3PsGwoXOhJPQAvicmu6RqOww/0, createdBy=a0bf1958339, createdName=七九九八, createdTime=Mon Jul 03 12:09:08 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471542, encodeId=ec5d14e1542a1, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Wed Jun 28 13:44:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595971, encodeId=aeee15959e1b1, content=<a href='/topic/show?id=07bfe3495f1' target=_blank style='color:#2F92EE;'>#砷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73495, encryptionId=07bfe3495f1, topicName=砷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=863418313756, createdName=lishizhe, createdTime=Wed Jun 28 13:44:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216146, encodeId=261c2161460f, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Wed Jun 28 06:13:34 CST 2017, time=2017-06-28, status=1, ipAttribution=)]
    2017-07-10 七九九八

    继续努力

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2022557, encodeId=4ab0202255edf, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Mon Jan 01 21:44:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909209, encodeId=74fb19092095d, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Wed Jul 19 13:44:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715569, encodeId=34d61e1556939, content=<a href='/topic/show?id=a217e58972' target=_blank style='color:#2F92EE;'>#food#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7589, encryptionId=a217e58972, topicName=food)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68d031960225, createdName=ms6747015003810650, createdTime=Mon Jan 15 02:44:00 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061636, encodeId=bbb22061636a7, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Nov 17 18:44:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=220629, encodeId=18ac22062979, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCcmyvDOwDu2ZpuYyovmsD12IBHmUCwr5bZqNic2p50ogCxUAIj4YqJ3PsGwoXOhJPQAvicmu6RqOww/0, createdBy=a0bf1958339, createdName=七九九八, createdTime=Mon Jul 10 08:02:21 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218933, encodeId=fba221893365, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCcmyvDOwDu2ZpuYyovmsD12IBHmUCwr5bZqNic2p50ogCxUAIj4YqJ3PsGwoXOhJPQAvicmu6RqOww/0, createdBy=a0bf1958339, createdName=七九九八, createdTime=Wed Jul 05 22:22:49 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218116, encodeId=cba0218116db, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCcmyvDOwDu2ZpuYyovmsD12IBHmUCwr5bZqNic2p50ogCxUAIj4YqJ3PsGwoXOhJPQAvicmu6RqOww/0, createdBy=a0bf1958339, createdName=七九九八, createdTime=Mon Jul 03 12:09:08 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471542, encodeId=ec5d14e1542a1, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Wed Jun 28 13:44:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595971, encodeId=aeee15959e1b1, content=<a href='/topic/show?id=07bfe3495f1' target=_blank style='color:#2F92EE;'>#砷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73495, encryptionId=07bfe3495f1, topicName=砷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=863418313756, createdName=lishizhe, createdTime=Wed Jun 28 13:44:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216146, encodeId=261c2161460f, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Wed Jun 28 06:13:34 CST 2017, time=2017-06-28, status=1, ipAttribution=)]
    2017-07-05 七九九八

    继续努力

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2022557, encodeId=4ab0202255edf, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Mon Jan 01 21:44:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909209, encodeId=74fb19092095d, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Wed Jul 19 13:44:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715569, encodeId=34d61e1556939, content=<a href='/topic/show?id=a217e58972' target=_blank style='color:#2F92EE;'>#food#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7589, encryptionId=a217e58972, topicName=food)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68d031960225, createdName=ms6747015003810650, createdTime=Mon Jan 15 02:44:00 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061636, encodeId=bbb22061636a7, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Nov 17 18:44:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=220629, encodeId=18ac22062979, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCcmyvDOwDu2ZpuYyovmsD12IBHmUCwr5bZqNic2p50ogCxUAIj4YqJ3PsGwoXOhJPQAvicmu6RqOww/0, createdBy=a0bf1958339, createdName=七九九八, createdTime=Mon Jul 10 08:02:21 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218933, encodeId=fba221893365, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCcmyvDOwDu2ZpuYyovmsD12IBHmUCwr5bZqNic2p50ogCxUAIj4YqJ3PsGwoXOhJPQAvicmu6RqOww/0, createdBy=a0bf1958339, createdName=七九九八, createdTime=Wed Jul 05 22:22:49 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218116, encodeId=cba0218116db, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCcmyvDOwDu2ZpuYyovmsD12IBHmUCwr5bZqNic2p50ogCxUAIj4YqJ3PsGwoXOhJPQAvicmu6RqOww/0, createdBy=a0bf1958339, createdName=七九九八, createdTime=Mon Jul 03 12:09:08 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471542, encodeId=ec5d14e1542a1, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Wed Jun 28 13:44:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595971, encodeId=aeee15959e1b1, content=<a href='/topic/show?id=07bfe3495f1' target=_blank style='color:#2F92EE;'>#砷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73495, encryptionId=07bfe3495f1, topicName=砷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=863418313756, createdName=lishizhe, createdTime=Wed Jun 28 13:44:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216146, encodeId=261c2161460f, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Wed Jun 28 06:13:34 CST 2017, time=2017-06-28, status=1, ipAttribution=)]
    2017-07-03 七九九八

    继续努力

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2022557, encodeId=4ab0202255edf, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Mon Jan 01 21:44:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909209, encodeId=74fb19092095d, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Wed Jul 19 13:44:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715569, encodeId=34d61e1556939, content=<a href='/topic/show?id=a217e58972' target=_blank style='color:#2F92EE;'>#food#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7589, encryptionId=a217e58972, topicName=food)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68d031960225, createdName=ms6747015003810650, createdTime=Mon Jan 15 02:44:00 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061636, encodeId=bbb22061636a7, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Nov 17 18:44:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=220629, encodeId=18ac22062979, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCcmyvDOwDu2ZpuYyovmsD12IBHmUCwr5bZqNic2p50ogCxUAIj4YqJ3PsGwoXOhJPQAvicmu6RqOww/0, createdBy=a0bf1958339, createdName=七九九八, createdTime=Mon Jul 10 08:02:21 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218933, encodeId=fba221893365, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCcmyvDOwDu2ZpuYyovmsD12IBHmUCwr5bZqNic2p50ogCxUAIj4YqJ3PsGwoXOhJPQAvicmu6RqOww/0, createdBy=a0bf1958339, createdName=七九九八, createdTime=Wed Jul 05 22:22:49 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218116, encodeId=cba0218116db, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCcmyvDOwDu2ZpuYyovmsD12IBHmUCwr5bZqNic2p50ogCxUAIj4YqJ3PsGwoXOhJPQAvicmu6RqOww/0, createdBy=a0bf1958339, createdName=七九九八, createdTime=Mon Jul 03 12:09:08 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471542, encodeId=ec5d14e1542a1, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Wed Jun 28 13:44:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595971, encodeId=aeee15959e1b1, content=<a href='/topic/show?id=07bfe3495f1' target=_blank style='color:#2F92EE;'>#砷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73495, encryptionId=07bfe3495f1, topicName=砷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=863418313756, createdName=lishizhe, createdTime=Wed Jun 28 13:44:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216146, encodeId=261c2161460f, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Wed Jun 28 06:13:34 CST 2017, time=2017-06-28, status=1, ipAttribution=)]
    2017-06-28 ylz8405
  9. [GetPortalCommentsPageByObjectIdResponse(id=2022557, encodeId=4ab0202255edf, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Mon Jan 01 21:44:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909209, encodeId=74fb19092095d, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Wed Jul 19 13:44:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715569, encodeId=34d61e1556939, content=<a href='/topic/show?id=a217e58972' target=_blank style='color:#2F92EE;'>#food#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7589, encryptionId=a217e58972, topicName=food)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68d031960225, createdName=ms6747015003810650, createdTime=Mon Jan 15 02:44:00 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061636, encodeId=bbb22061636a7, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Nov 17 18:44:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=220629, encodeId=18ac22062979, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCcmyvDOwDu2ZpuYyovmsD12IBHmUCwr5bZqNic2p50ogCxUAIj4YqJ3PsGwoXOhJPQAvicmu6RqOww/0, createdBy=a0bf1958339, createdName=七九九八, createdTime=Mon Jul 10 08:02:21 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218933, encodeId=fba221893365, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCcmyvDOwDu2ZpuYyovmsD12IBHmUCwr5bZqNic2p50ogCxUAIj4YqJ3PsGwoXOhJPQAvicmu6RqOww/0, createdBy=a0bf1958339, createdName=七九九八, createdTime=Wed Jul 05 22:22:49 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218116, encodeId=cba0218116db, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCcmyvDOwDu2ZpuYyovmsD12IBHmUCwr5bZqNic2p50ogCxUAIj4YqJ3PsGwoXOhJPQAvicmu6RqOww/0, createdBy=a0bf1958339, createdName=七九九八, createdTime=Mon Jul 03 12:09:08 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471542, encodeId=ec5d14e1542a1, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Wed Jun 28 13:44:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595971, encodeId=aeee15959e1b1, content=<a href='/topic/show?id=07bfe3495f1' target=_blank style='color:#2F92EE;'>#砷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73495, encryptionId=07bfe3495f1, topicName=砷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=863418313756, createdName=lishizhe, createdTime=Wed Jun 28 13:44:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216146, encodeId=261c2161460f, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Wed Jun 28 06:13:34 CST 2017, time=2017-06-28, status=1, ipAttribution=)]
    2017-06-28 lishizhe
  10. [GetPortalCommentsPageByObjectIdResponse(id=2022557, encodeId=4ab0202255edf, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Mon Jan 01 21:44:00 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909209, encodeId=74fb19092095d, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Wed Jul 19 13:44:00 CST 2017, time=2017-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715569, encodeId=34d61e1556939, content=<a href='/topic/show?id=a217e58972' target=_blank style='color:#2F92EE;'>#food#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7589, encryptionId=a217e58972, topicName=food)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68d031960225, createdName=ms6747015003810650, createdTime=Mon Jan 15 02:44:00 CST 2018, time=2018-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061636, encodeId=bbb22061636a7, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Fri Nov 17 18:44:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=220629, encodeId=18ac22062979, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCcmyvDOwDu2ZpuYyovmsD12IBHmUCwr5bZqNic2p50ogCxUAIj4YqJ3PsGwoXOhJPQAvicmu6RqOww/0, createdBy=a0bf1958339, createdName=七九九八, createdTime=Mon Jul 10 08:02:21 CST 2017, time=2017-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218933, encodeId=fba221893365, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCcmyvDOwDu2ZpuYyovmsD12IBHmUCwr5bZqNic2p50ogCxUAIj4YqJ3PsGwoXOhJPQAvicmu6RqOww/0, createdBy=a0bf1958339, createdName=七九九八, createdTime=Wed Jul 05 22:22:49 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218116, encodeId=cba0218116db, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCcmyvDOwDu2ZpuYyovmsD12IBHmUCwr5bZqNic2p50ogCxUAIj4YqJ3PsGwoXOhJPQAvicmu6RqOww/0, createdBy=a0bf1958339, createdName=七九九八, createdTime=Mon Jul 03 12:09:08 CST 2017, time=2017-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471542, encodeId=ec5d14e1542a1, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Wed Jun 28 13:44:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595971, encodeId=aeee15959e1b1, content=<a href='/topic/show?id=07bfe3495f1' target=_blank style='color:#2F92EE;'>#砷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73495, encryptionId=07bfe3495f1, topicName=砷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=863418313756, createdName=lishizhe, createdTime=Wed Jun 28 13:44:00 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216146, encodeId=261c2161460f, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Wed Jun 28 06:13:34 CST 2017, time=2017-06-28, status=1, ipAttribution=)]
    2017-06-28 刘煜

    学习了谢谢分享

    0

相关资讯

Cancer Discov:三位一体全新血液检测技术,可为前列腺癌患者提供精准治疗

我们距离前列腺癌的精准医学更近了一步。研究人员已创建了一种三位一体的血液检测,他们声称这种检测技术能够预测前列腺癌或者对PARP抑制剂的反应,还有药物如何影响生存率,以及患者产生耐药性的可能性有多大。

Cell Chem Biol:新一代前列腺癌药物之间的相似之处

近日,发表于《细胞化学生物学》上的文章为前列腺的治疗奠定了基础,在此次研究中,科学家首次阐述了新一代前列腺癌药物在体内的运作机制,并如何根据代谢来决定肿瘤的活性。

Prostate Int:刺龙菊木提取物对亚硝基甲基脲(NMU)诱导的前列腺癌具有保护性作用

最近,有研究人员评估了刺龙菊木提取物对小鼠中亚硝基甲基脲(NMU)诱导的前列腺癌和DU-145细胞系可能保护作用。研究人员通过提供环丙氯地孕酮、睾酮和亚硝基甲基脲在30只雄性霍尔茨曼小鼠中诱导前列腺癌的形成。研究人员对肿瘤进行了检测,并记录了血液学和生化参数以及嗜多染红细胞微核数目。并通过细胞毒性试验对细胞系进行评估。研究发现,对小鼠进行刺龙菊木提取物口服给药可以显著的降低超氧化物歧化酶丙二醛、N

Clin Oncol:患有局部前列腺癌的70岁及以上并且经历根治性放射性治疗的患者的综合性老年人评估

70岁及以上且患有局部前列腺癌的男性的治疗选择是需要考虑很多因素的,比如来自竞争原因的死亡风险和拟治疗的适合度。客观的评估,比如那些包括在综合性老年人评估(CGA)中的内容也许可以帮助治疗方案的决定过程。最近,有研究人员进行了旨在描述一个患有前列腺癌男性老人群体的CGA得分,并且评估了潜在的筛选工具以及评估是否CGA内容可以预测重大急性放射毒性。该研究是个预期性的群体研究,并进行了CGA的预处理,

Brit J Cancer:肿瘤异质性给癌症生物标记研究带来了巨大挑战

癌症的高度基因组多样性表明了鉴定目标预后标记的巨大挑战。最近,有研究人员调查了重力异质性的程度以及对选择的预后标记的评估的影响,并且以前列腺癌作为模型进行研究。研究人员在赖在304名病人的根治性前列腺切除术标本(RP)中,评估了格林森得分(GS)、DNA倍体状态和磷酸化以及张力蛋白同系物(PTEN)的表达,这些病人跟踪调查时间的中值为10年(范围为6-12年)。研究人员对每一个肿瘤块进行了GS评估

Cance Cell:ACK1/TNK2调节去势抵抗性前列腺癌中组蛋白H4 Tyr88的磷酸化和雄激素受体基因的表达

在前列腺癌发展到去势抵抗性(CRPC)阶段的过程中,雄激素受体(AR)发挥着关键作用。雄激素受体抑制剂不能抑制AR或它的剪接异构体AR-V7的表达,因而没有治疗效果。本研究报道,在AR转录起始位点的上游,酪氨酸激酶ACK1(TNK2)在酪氨酸88上磷酸化组蛋白H4。WDR5/MLL2复合物读取H4-Y88磷酸化标记并沉淀转录性活化H3K4-三甲基标记,从而促进AR转录。以ACK1抑制剂(R)-9b